Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

14.1K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
14.1K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

9.4K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.4K
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

2.6K
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

8.0K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
8.0K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

11.0K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
11.0K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

9.4K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
9.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tryptophan Metabolism at the Crossroads of Immunity, Barrier Function, and the Microbiome in Atopic Dermatitis.

Clinical reviews in allergy & immunology·2026
Same author

Molecular insights into the role of vitamin D in atopic dermatitis: pathogenesis, diagnosis, and emerging therapies.

Frontiers in immunology·2026
Same author

Ramulus Mori (Sangzhi) alkaloids attenuate diet-induced obesity by modulating adipose tissue metabolic programs.

Scientific reports·2026
Same author

Betacellulin, a member of the EGF family, ameliorates atopic dermatitis-like symptoms via EGFR-JNK/ERK-mediated activation of autophagy.

Allergology international : official journal of the Japanese Society of Allergology·2026
Same author

E-nose, HS-SPME-GC-MS and untargeted metabolomics reveal effects on <sup>60</sup>Co gamma irradiation of Neng-An-Jun-Ning Pills: Changes in odor and chemical compositions.

Journal of pharmaceutical and biomedical analysis·2026
Same author

Decreased S100A7 expression is linked to altered differentiation-, autophagy- and senescence-related programs during skin aging.

npj aging·2026

Related Experiment Video

Updated: Apr 14, 2026

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
12:34

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Published on: January 12, 2024

1.4K

Targeting the JAK/STAT pathway in atopic dermatitis.

Lixia Cui1, Pengyue Liu2, Kun Wu1

  • 1Department of Dermatology and Venereology, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.

Frontiers in Immunology
|April 13, 2026
PubMed
Summary
This summary is machine-generated.

Janus kinase (JAK) inhibitors offer new treatments for atopic dermatitis (AD) by targeting the JAK/STAT pathway involved in skin inflammation. Research is ongoing to refine these therapies for safer and more personalized patient care.

Keywords:
JAK inhibitorsJAK/STAT signalingatopic dermatitisbiologic therapyimmunopathogenesisskin inflammation

More Related Videos

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

10.3K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

957

Related Experiment Videos

Last Updated: Apr 14, 2026

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
12:34

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Published on: January 12, 2024

1.4K
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

10.3K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

957

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Atopic dermatitis (AD) is a chronic inflammatory skin condition involving immune dysregulation and skin barrier defects.
  • The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway is crucial in mediating inflammatory responses in AD, including key cytokines like IL-4, IL-13, and IL-31.
  • Current treatments for AD are evolving, with JAK inhibitors emerging as significant therapeutic options for patients with moderate-to-severe disease.

Purpose of the Study:

  • To provide a comprehensive review of the JAK/STAT pathway's role in the pathogenesis of atopic dermatitis.
  • To summarize and compare the efficacy and safety of current and investigational JAK inhibitors for AD treatment.
  • To explore future directions and innovations in JAK/STAT-targeted therapies for AD management.

Main Methods:

  • This narrative review synthesizes information from existing literature on the JAK/STAT pathway and its inhibition in atopic dermatitis.
  • Key studies and clinical trial data on JAK inhibitors were analyzed for efficacy, safety, and therapeutic outcomes.
  • Future research trends, including precision medicine and novel drug delivery systems, were identified and discussed.

Main Results:

  • The JAK/STAT pathway plays a central role in driving T-helper 2-skewed inflammation and impairing skin barrier function in AD.
  • JAK inhibitors have demonstrated significant efficacy in managing AD symptoms and improving skin barrier function in clinical studies.
  • Varied efficacy and safety profiles exist among different JAK inhibitors, with ongoing research addressing long-term outcomes and potential adverse effects.

Conclusions:

  • Targeting the JAK/STAT pathway represents a significant advancement in atopic dermatitis treatment, offering effective options for patients.
  • Further research is essential to optimize JAK inhibitor therapy, focusing on personalized treatment strategies, safety, and long-term efficacy.
  • Future innovations hold promise for developing more targeted, safer, and individualized approaches to managing atopic dermatitis through refined JAK/STAT pathway modulation.